DIAMEDICA THERAPEUTICS INC's ticker is DMAC and the CUSIP is 25253X207. A total of 27 filers reported holding DIAMEDICA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,788 | +6.5% | 4,335 | 0.0% | 0.00% | – |
| Q1 2024 | $12,008 | -2.5% | 4,335 | 0.0% | 0.00% | – |
| Q4 2023 | $12,311 | +10.1% | 4,335 | 0.0% | 0.00% | – |
| Q3 2023 | $11,184 | -40.3% | 4,335 | 0.0% | 0.00% | – |
| Q2 2023 | $18,727 | +182.3% | 4,335 | 0.0% | 0.00% | – |
| Q1 2023 | $6,633 | -3.2% | 4,335 | 0.0% | 0.00% | – |
| Q4 2022 | $6,850 | +37.0% | 4,335 | 0.0% | 0.00% | – |
| Q3 2022 | $5,000 | -44.4% | 4,335 | 0.0% | 0.00% | – |
| Q2 2022 | $9,000 | -18.2% | 4,335 | 0.0% | 0.00% | – |
| Q1 2022 | $11,000 | -31.2% | 4,335 | 0.0% | 0.00% | – |
| Q4 2021 | $16,000 | -5.9% | 4,335 | 0.0% | 0.00% | – |
| Q3 2021 | $17,000 | -10.5% | 4,335 | 0.0% | 0.00% | – |
| Q2 2021 | $19,000 | -52.5% | 4,335 | 0.0% | 0.00% | – |
| Q1 2021 | $40,000 | -9.1% | 4,335 | 0.0% | 0.00% | – |
| Q4 2020 | $44,000 | +144.4% | 4,335 | 0.0% | 0.00% | – |
| Q3 2020 | $18,000 | – | 4,335 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 500,000 | $1,420,000 | 3.26% |
| Altium Capital Management LP | 287,698 | $817,062 | 0.56% |
| Bleichroeder LP | 222,317 | $631,380 | 0.14% |
| COOPERMAN LEON G | 1,767,246 | $5,018,978 | 0.12% |
| Aristides Capital LLC | 106,333 | $301,986 | 0.11% |
| CATALYST FINANCIAL PARTNERS LLC | 36,267 | $102,998 | 0.03% |
| Naples Money Management LLC | 3,878 | $11,014 | 0.01% |
| Stonebridge Capital Advisors LLC | 20,000 | $56,800 | 0.01% |
| Legend Financial Advisors, Inc. | 1,000 | $2,840 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 114,744 | $325,872 | 0.00% |